

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22820 A1

- (51) International Patent Classification⁷: C12N 15/12, 9/64, 15/62, C07K 14/705 (74) Agents: MANDRAGOURAS, Amy, E. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).
- (21) International Application Number: PCT/US00/25007 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 12 September 2000 (12.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US). MONTREAL HEART INSTITUTE [CA/CA]; 5000 Belanger East, Montreal, Quebec H1T 1C8 (CA).
- (72) Inventors: KUMAR, Anjali; 27 Tulip Circle, Haverhill, MA 01830 (US). SCHUAB, Robert, G.; 118 Jeremy Hill Road, Pelham, NH (US). TANGUAY, Jean-Francois; CP 323 Succursale, Mount Royale, Montreal, Quebec H3P 3C5 (CA). MERHI, Yahye; 12 Laniel, Dollard-des-Ormeaux, Quebec H9B 3G5 (CA).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/22820 A1

(54) Title: INHIBITION OF STENOSIS OR RESTENOSIS BY P-SELECTIN ANTAGONISTS

(57) Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.

INHIBITION OF STENOSIS OR RESTENOSIS BY P-SELECTIN ANTAGONISTS

Background of the Invention

Coronary artery disease is a major cause of morbidity and mortality in the Western world. The disease is typically manifested in intravascular stenosis (narrowing) or occlusion (blockage) due to atherosclerotic plaque. Percutaneous transluminal coronary balloon angioplasty (PTCA), for example, is widely used as the primary treatment for arteriosclerosis involving stenosis. PTCA is any percutaneous transluminal method of decreasing stenosis within a blood vessel. PTCA has an immediate success rate of more than 95%, but long term success remains limited by restenosis in 20-50% of patients within six months after intervention (Bult, H. (2000) *Trends in Pharmacological Sciences* 21:274-279). Stent implantation may improve the clinical outcome of PTCA, however, restenosis still remains a major clinical challenge. Indeed, restenosis is the single most significant problem in interventional cardiology and costs the health care system in excess of \$1 billion per year.

Restenosis, the process of arterial re-narrowing, is a combination of neointimal formation and arterial remodeling in response to vascular injury such as that resulting from PTCA or other initially successful intervention. Vascular remodeling has a significant impact on chronic lumen area and may be responsible for 50% to 90% of late luminal area loss (Kumar, *et al.* (1997) *Circulation* 96(12):4333-4342). Remodeling is an adaptive process that occurs in response to chronic changes in hemodynamic conditions and may involve changes in many processes, such as cell growth, cell death, cell migration, and changes in extracellular matrix composition, that lead to a compensatory adjustment in vessel diameter and lumen area. The blood vessel is thought to remodel itself in response to long-term changes in flow, such that the lumen area is modified to maintain a predetermined level of shear stress (Kumar, *et al.* (1997) *Circulation* 96(12):4333-4342 and Orrego, *et al.* (1999) *Cardiologia* 44(7)621).

Inflammatory reactions such as activation of granulocytes and neutrophils and platelet accumulation occur after PTCA. P-selectin rapidly appears on the cell surface of platelets when they are activated, mediating calcium-dependent adhesion of neutrophils or monocytes to platelets. P-selectin is also found in the Weibel-Palade bodies of endothelial cells; upon its release from these vesicles P-selectin mediates early binding of neutrophils to histamine-or thrombin-stimulated endothelium. In addition, selectins have been implicated in mediating interactions between endothelial cells and leukocytes in what is known as "leukocyte rolling," which is generally believed to be the prerequisite for firm adhesion and subsequent transendothelial migration of leukocytes into tissues (Moore, (1998) *Leuk Lymphoma* 29(1-2):1-15). Thus far three human selectin proteins have been identified, E-selectin (formerly ELAM-1), L-selectin (formerly LAM-1) and P-selectin (formerly

PADGEM or GMP-140). The selectin proteins are characterized by a N-terminal lectin-like domain, an epidermal growth factor-like domain, and regions of homology to complement binding proteins.

Selectins are believed to mediate adhesion through specific interactions with ligands present on the surface of target cells, *e.g.*, platelets. Generally the ligands of selectins are comprised at least in part of a carbohydrate moiety (*e.g.*, sialyl Lewis^x (sLe^x) and sialyl Lewis^a (sLe^a)). P-selectin binds to carbohydrates containing the non-sialated form of the Lewis^x blood group antigen and with higher affinity to sialyl Lewis^x. P-selectin Glycoprotein Ligand-1 (PSGL-1), a high-affinity P-selectin ligand, is expressed by leukocytes and platelets and mediates cell adhesion between these cell types (U.S. Patent Number 5,843,707 and U.S. Patent Number 5,827,817).

Summary of the Invention

The present invention provides methods and compositions for the modulation, (*e.g.*, prevention, inhibition, and treatment) of stenosis and restenosis. The present invention is based, at least in part, on the discovery that P-selectin antagonism by P-selectin antagonists, including P-selectin ligand molecules, anti-P-selectin antibodies, and anti-P-selectin ligand antibodies inhibit cellular adhesion, *e.g.*, platelet-leukocyte adhesion at the site of vascular injury, inhibit neointimal formation, and modulate vascular remodeling when administered to a subject with vascular injury or cardioidisease. The P-selectin molecules of the invention are referred to herein as P-Selectin Glycoprotein Ligand-1 (PSGL-1) molecules.

Platelet-leukocyte adhesion, neointimal formation, and constrictive vascular remodeling all contribute to lumen loss and stenosis. Accordingly, P-selectin antagonists (*e.g.*, PSGL-1 molecules, anti-P-selectin antibodies, and anti-P-selectin ligand antibodies) are useful agents in the modulation of stenosis and restenosis.

In one aspect, the invention provides a method for modulating stenosis and restenosis in a subject having vascular injury or cardioidisease, comprising administering a P-selectin antagonist. In one embodiment, the P-selectin antagonist is a P-selectin ligand protein. In a preferred embodiment, the P-selectin antagonist comprises a soluble P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity, *e.g.*, soluble PSGL-1 or a soluble recombinant PSGL fusion protein, *e.g.*, rPSGL-Ig. In another embodiment, the P-selectin antagonist comprises an anti-P-selectin antibody or an anti-P-selectin ligand antibody. In a yet another embodiment, the composition further comprises a pharmaceutically acceptable carrier.

In one embodiment of the invention, stenosis and restenosis are characterized by constrictive vascular remodeling. In another embodiment, stenosis and restenosis are characterized by neointimal formation. In one embodiment the subject is a mammal, *e.g.*, a human. In another embodiment, the P-selectin antagonist is administered to the subject

prior to vascular injury. Vascular injury may result from, for example, coronary artery surgery, carotid artery surgery, angioplasty, *e.g.*, percutaneous transluminal coronary angioplasty (PTCA), or implantation of one or more stents.

In another embodiment, the methods of the invention includes the administration of a
5 soluble P-selectin ligand protein comprising at least a portion of an extracellular domain of a P-selectin ligand protein, for example, amino acid 42 to 60, 42 to 88, 42 to 118, 42 to 189, 42 to 310, or 42 to 316 of the amino acid sequence set forth in SEQ ID NO:2. In another embodiment, the protein comprises a soluble P-selectin ligand protein comprising at least an extracellular domain of a P-selectin ligand protein, for example, amino acids 21-316 of the
10 amino acid sequence set forth in SEQ ID NO:2. In a further embodiment, the invention provides that the soluble protein comprises an Fc portion of an immunoglobulin, *e.g.*, human IgG. In a related embodiment, the soluble protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence from amino acid 42 to amino acid 60 of SEQ ID NO:2 fused at its C-terminus to the Fc portion of an immunoglobulin. In a related
15 embodiment, the soluble protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence from amino acid 42 to amino acid 88 of SEQ ID NO:2 fused at its C-terminus to the Fc portion of an immunoglobulin. In one embodiment, the amino acid sequence is fused through a linking sequence.

Another aspect of the invention provides a method for modulating leukocyte
20 recruitment in a subject comprising administering a P-selectin antagonist, *e.g.*, a PSGL-1, anti-P-selectin ligand antibody, or an anti-P-selectin antibody. Yet another aspect of the invention provides a method for inhibiting cell to cell adhesion in a subject comprising administering a P-selectin antagonist, *e.g.*, soluble PSGL-1, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. In one embodiment, the adhesive cells are selected
25 from the group consisting of leukocytes, platelets, and endothelial cells. A further aspect of the invention provides a method for inhibiting cell adhesion to blood vessels in a subject comprising administering a P-selectin antagonist, *e.g.*, soluble PSGL-1, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody, thereby inhibiting cell adhesion to blood vessels. In one embodiment, the adhesive cells are selected from the group consisting of
30 leukocytes, platelets and endothelial cells.

In yet another aspect, the invention provides a method for identifying a compound capable of modulating stenosis or restenosis comprising assaying the ability of the compound to modulate PSGL-1 protein activity. In one embodiment, the ability of the compound to modulate PSGL-1 polypeptide activity is determined by detecting a decrease
35 in intercellular adhesion. For example, cellular adhesion may involve leukocytes, endothelial cells, or platelets. In another embodiment, the ability of the compound to modulate PSGL-1 polypeptide activity is determined by detecting positive vascular remodeling after vascular injury. In yet another embodiment, the ability of the compound to

modulate PSGL-1 polypeptide activity is determined by detecting a reduction of neointimal formation.

Other features and advantages of the invention will be apparent from the following
5 detailed description and claims.

Brief Description of the Drawings

Figure 1 is a graph depicting platelet adhesion to deeply damaged arterial segments at 1 and 4 hours and at 1 and 4 weeks post-angioplasty in control and rPSGL-Ig-treated pigs.

10 *Figure 2* is a graph depicting neutrophil adhesion to deeply damaged arterial segments at 1 and 4 hours and 1 and 4 weeks post-angioplasty in control and rPSGL-Ig-treated pigs.

Figure 3 is a graph illustrating the correlation between vascular stenosis and normalized external elastic lamina (EEL) surface in control and rPSGL-Ig-treated pig
15 arteries at 4 weeks.

Figure 4 is a graph illustrating the correlation between vascular stenosis and neointimal surface area in control and rPSGL-Ig-treated pig arteries at 4 weeks.

Figure 5 is a graph depicting the external elastic lumina (EEL) surface and residual lumen in control and rPSGL-Ig-treated pig arteries at 1 and 4 weeks.

20 *Figure 6* depicts the morphology of arterial sections and expression of P-selectin by neoendothelium at 4 weeks in control and rPSGL-Ig-treated pig arteries.

Detailed Description of the Invention

The present invention provides methods and compositions for the modulation, *e.g.*,
25 treatment, inhibition, or prevention of stenosis or restenosis, *in vivo*, by administration of P-selectin antagonists, *e.g.*, P-selectin ligand molecules, anti-P-selectin antibodies, and anti-P-selectin ligand antibodies. The P-selectin ligand molecules used in the methods of the invention are referred to herein as P-Selectin Glycoprotein Ligand -1 (PSGL-1) molecules.

The P-selectin antagonists of the methods of the invention can be used to modulate
30 cell-cell adhesion, *e.g.*, platelet-leukocyte adhesion, neointimal formation, and vascular remodeling in a subject where the subject has vascular injury resulting from cardiovascular disease, *e.g.*, arteriosclerosis, or non-pathologic vascular intervention, *e.g.*, PCTA or stent implantation, and are, accordingly, useful in modulating stenosis or restenosis. In another embodiment, the P-selectin antagonists of the methods of the invention can be used to
35 modulate restenosis in a subject where the subject has vascular injury and subsequently undergoes vascular intervention, such as angioplasty or stent implantation.

Platelets and leukocytes adhere to damaged arterial walls after vascular injury through binding between P-selectin and PSGL-1, which is expressed on leukocytes and

platelets. In one aspect of the invention, antagonism of P-selectin by a P-selectin ligand, an anti-P-selectin antibody, or an anti-P-selectin ligand antibody inhibits both platelet and neutrophil adhesion to damaged arterial segments, thereby modulating restenosis (see Example 2 and Figures 1 and 2). Interaction between platelets and leukocytes, *e.g.*,
5 intercellular adhesion, is also inhibited by the P-selectin antagonists of the invention.

In another aspect of the invention, administering a P-selectin antagonist to a subject with vascular injury, where the subject is undergoing subsequent vascular intervention resulting in further vascular injury, results in a larger residual lumen and a larger external elastic lumina (EEL) post-injury (see Table 2 in Example 2 and Figures 5 and 6), compared
10 to a control, thereby positively impacting vascular remodeling. As demonstrated herein, in animals having prior vascular injury that are treated with a P-selectin antagonist, *e.g.*, soluble rPSGL-Ig, prior to a second vascular injury, the percentage of vascular restenosis is significantly less ($p < 0.005$) than in control animals. Accordingly, restenosis is modulated, *e.g.*, prevented, inhibited, or treated, by administration of a P-selectin antagonist (see
15 Examples 2). In yet another aspect of the invention, P-selectin antagonism inhibits neointimal formation. In one embodiment, a subject who has prior vascular injury and is undergoing stent implantation is treated by the administration of a P-selectin antagonist to thereby inhibit neointimal formation in the subject. Accordingly, stenosis and restenosis are inhibited (see Example 3).

As used herein, a "P-selectin antagonist" includes any agents which are capable of antagonizing P-selectin, *e.g.*, by inhibiting interaction between P-selectin and a P-selectin ligand protein, *e.g.*, by inhibiting interaction of P-selectin expressing platelets with PSGL
20 expressing leukocytes. For example, P-selectin antagonists include anti-P-selectin antibodies, anti-P-selectin ligand antibodies, P-selectin ligand molecules, *e.g.* PSGL-1, or
25 fragments thereof having P-selectin ligand activity as well as small molecules. In a preferred embodiment, the P-selectin ligand is soluble.

As used interchangeably herein, "P-selectin ligand activity," "PSGL-1 activity," "biological activity of PSGL-1" or "functional activity of PSGL-1," includes an activity exerted by a PSGL-1 protein, polypeptide or nucleic acid molecule on a PSGL-1 responsive
30 cell, *e.g.*, platelet, leukocyte, or endothelial cell, as determined *in vivo*, or *in vitro*, according to standard techniques. PSGL-1 activity can be a direct activity, such as an association with a PSGL-1-target molecule *e.g.*, P-selectin. As used herein, a "substrate" or "target molecule" or "binding partner" is a molecule, *e.g.* P-selectin, with which a PSGL-1 protein binds or
interacts in nature, such that PSGL-1-mediated function, *e.g.*, modulation of cell migration
35 or adhesion, is achieved. A PSGL-1 target molecule can be a non-PSGL-1 molecule or a PSGL-1 protein or polypeptide. Examples of such target molecules include proteins in the same signaling path as the PSGL-1 protein, *e.g.*, proteins which may function upstream (including both stimulators and inhibitors of activity) or downstream of the PSGL-1 protein

in a pathway involving regulation of P-selectin binding. Alternatively, a PSGL-1 activity is an indirect activity, such as a cellular signaling activity mediated by interaction of the PSGL-1 protein with a PSGL-1 target molecule. The biological activities of PSGL-1 are described herein, and include, for example, one or more of the following activities: 1)

- 5 binding to or interacting with P-selectin; 2) modulating P-selectin binding; 2) modulating intercellular adhesion, *e.g.*, platelet-leukocyte adhesion and endothelial-leukocyte adhesion; 3) modulating cell migration, *e.g.*, leukocyte recruitment to platelets and endothelial cells; 4) modulating stenosis or restenosis; 5) modulating vascular remodeling; and 6) modulating neointimal formation.

- 10 As used herein, "stenosis" includes the process of arterial narrowing. "Restenosis" includes the process of arterial re-narrowing following initially successful vascular intervention. Stenosis and restenosis are characterized by neointimal formation (*e.g.*, intimal thickening), and constrictive vascular remodeling in response to vascular injury such as that resulting from percutaneous transluminal coronary angioplasty (PTCA) or other
15 initially successful intervention (restenosis), or in response to vascular injury resulting from pathogenic stimuli, *e.g.*, vascular or cardiovascular disease (stenosis). Vascular remodeling is an adaptive process of structural changes in vascular wall structures, and involves changes in many processes, such as cell growth, cell death, cell migration, intercellular adhesion, and changes in extracellular matrix composition, that lead to a compensatory adjustment in
20 vessel diameter and lumen area. In the context of restenosis or stenosis, vascular remodeling refers to a loss of lumen area by a combination of reduction in vessel diameter and neointimal thickening (*e.g.*, constrictive vascular remodeling). As used herein, "positive vascular remodeling" includes an increase in the lumen area of a vessel, or an increase in vessel diameter. Positive vascular remodeling also includes a lack of
25 constrictive vascular remodeling, *e.g.*, a decrease in lumen area of a vessel or a decrease in vessel diameter, after vascular injury caused by vascular intervention or vascular disease.

- A subject who may be at risk for stenosis is one who suffers from a cardiovascular disease or disorder. A subject who may be at risk for restenosis is one who is undergoing cardiovascular or general vascular procedures or intervention such as angioplasty of any
30 vessel, *e.g.*, carotid, femoral, coronary, etc.; surgical revascularization, *e.g.*, balloon angioplasty, laser angioplasty, percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting, rotational atherectomy or coronary artery stents, or other intervention, surgical or non-surgical, which may cause vascular injury. Administration of a P-selectin antagonist to modulate restenosis may be prior to injury, during the intervention
35 procedure, or after the injury or intervention has occurred. In a preferred embodiment, administration of the P-selectin antagonist is prior to surgical intervention.

The P-selectin ligand molecules used in the methods of the invention are described in U.S. Patent Numbers 5,827,817, 5,840,679, and 5,843,707, the contents of which are

incorporated herein by reference. PSGL-1 is a glycoprotein which acts as a ligand for P-selectin on endothelial cells and platelets. The DNA sequence of PSGL-1 is set forth in SEQ ID NO:1. The complete amino acid sequence of the PSGL-1, *i.e.*, the mature peptide plus the leader sequence, is characterized by the amino acid sequence set forth in SEQ ID NO:2 from amino acid 1 to amino acid 402. The mature PSGL-1 protein is characterized by the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 402.

As used herein, a "soluble PSGL-1 protein," or a "soluble P-selectin ligand protein," refers to a soluble P-selectin ligand glycoprotein, *e.g.*, soluble PSGL-1, or a fragment thereof having a P-selectin ligand activity, which includes a carbohydrate comprising sLe^x. Soluble P-selectin ligand proteins used in the methods of the invention preferably include at least an extracellular domain of PSGL-1, *e.g.*, about amino acid 21 to about amino acid 316 of SEQ ID NO:2. Other soluble forms of the P-selectin ligand molecules are characterized by the amino acid sequence set forth in SEQ ID NO:2 from amino acids 42 to 310. In one embodiment of the methods of the invention, soluble forms of the P-selectin ligand molecules of the methods of the invention may be fused through "linker" sequences to the Fc portion of an immunoglobulin, *e.g.*, an IgG molecule (see Example 1D). In another embodiment of the invention, the soluble P-selectin ligand protein is a chimeric molecule which is comprised of the extracellular domain of a PSGL-1 protein molecule, a carbohydrate comprising sLe^x, and is fused through linker sequences to the Fc portion of human IgG. This soluble form of PSGL-1 is referred to herein as soluble rPSGL-Ig.

The methods of the invention encompass the use of nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1 due to degeneracy of the genetic code and thus encode the same PSGL-1 proteins as those encoded by the nucleotide sequence shown in SEQ ID NO:1. In another embodiment, an isolated nucleic acid molecule included in the methods of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in SEQ ID NO:2.

The methods of the invention further include the use of allelic variants of human PSGL-1, *e.g.*, functional and non-functional allelic variants. Functional allelic variants are naturally occurring amino acid sequence variants of the human PSGL-1 protein that maintain a PSGL-1 activity as described herein, *e.g.*, P-selectin binding. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:2, or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein. Non-functional allelic variants are naturally occurring amino acid sequence variants of the human PSGL-1 protein that do not have a PSGL-1 activity. Non-functional allelic variants will typically contain a non-conservative substitution, deletion, or insertion or premature truncation of the amino acid sequence of SEQ ID NO:2, or a substitution, insertion or deletion in critical residues or critical regions of the protein.

Various aspects of the invention are described in further detail in the following subsections:

I. Isolated PSGL-1 Proteins, Anti-PSGL-1 Antibodies, and Anti-P-Selectin Antibodies
Used in the Methods of the Invention

The methods of the invention include the use of isolated P-selectin ligand proteins, *e.g.* PGSL-1 proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-P-selectin ligand antibodies. In one embodiment, native PSGL-1 proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, PSGL-1 proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a PSGL-1 protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

As used herein, a "biologically active portion" of a PSGL-1 protein includes a fragment of a PSGL-1 protein having a PSGL-1 activity. Biologically active portions of a PSGL-1 protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the PSGL-1 protein, *e.g.*, the amino acid sequence shown in SEQ ID NO:2, which include fewer amino acids than the full length PSGL-1 proteins, and exhibit at least one activity of a PSGL-1 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the PSGL-1 protein (*e.g.*, a fragment containing amino acids 42 to 60 of SEQ ID NO:2 is capable of interacting with P-selectin). A biologically active portion of a PSGL-1 protein can be a polypeptide which is, for example, 25, 50, 75, 100, 125, 150, 175, 200, 250, 300 or more amino acids in length. Biologically active portions of a PSGL-1 protein can be used as targets for developing agents which modulate a PSGL-1 activity.

In a preferred embodiment, the PSGL-1 protein used in the methods of the invention has at least an extracellular domain of the amino acid sequence shown in SEQ ID NO:2 or P-selectin binding fragment of the extracellular domain of PSGL-1, or an extracellular domain of SEQ ID NO:2. In other embodiments, the PSGL-1 protein is substantially identical to SEQ ID NO:2, and retains the functional activity of the protein of SEQ ID NO:2, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail in subsection II below. Accordingly, in another embodiment, the PSGL-1 protein used in the methods of the invention is a protein which comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO:2.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for

optimal alignment and non-identical sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence (e.g., when aligning a second sequence to the PSGL-1 amino acid sequence of SEQ ID NO:2 having 1600 amino acid residues, at least 480, preferably at least 640, more preferably at least 800, even more preferably at least 960, and even more preferably at least 1120, 1280, or 1440 or more amino acid residues are aligned). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Meyers and W. Miller (*Comput. Appl. Biosci.* 4:11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0 or 2.0U), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The methods of the invention may also use PSGL-1 chimeric or fusion proteins. As used herein, a PSGL-1 "chimeric protein" or "fusion protein" comprises a PSGL-1 polypeptide operatively linked to a non-PSGL-1 polypeptide. A "PSGL-1 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a PSGL-1 molecule, whereas a "non-PSGL-1 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the PSGL-1 protein, e.g., a protein which is different from the PSGL-1 protein and which is derived from the

same or a different organism. Within a PSGL-1 fusion protein the PSGL-1 polypeptide can correspond to all or a portion of a PSGL-1 protein. In a preferred embodiment, a PSGL-1 fusion protein comprises at least one biologically active portion of a PSGL-1 protein, *e.g.*, an extracellular domain of PSGL-1 or P-selectin binding fragment thereof. In another
5 preferred embodiment, a PSGL-1 fusion protein comprises at least two biologically active portions of a PSGL-1 protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the PSGL-1 polypeptide and the non-PSGL-1 polypeptide are fused in-frame to each other. The non-PSGL-1 polypeptide can be fused to the N-terminus or C-terminus of the PSGL-1 polypeptide.

10 For example, in one embodiment, the fusion protein is a recombinant soluble form of PSGL-1 protein in which the extracellular domain of the PSGL-1 molecule is fused to human IgG, *e.g.*, soluble rPSGL-Ig.

In another embodiment, this fusion protein is a PSGL-1 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host
15 cells), expression and/or secretion of PSGL-1 can be increased through use of a heterologous signal sequence.

The soluble PSGL-1 fusion proteins used in the methods of the invention, *e.g.* rPSGL-Ig, can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The soluble PSGL-1 fusion proteins can be used to affect the bioavailability
20 of a PSGL-1 substrate, *e.g.*, P-selectin.

Moreover, the PSGL-1-fusion proteins used in the methods of the invention can be used as immunogens to produce anti-P-selectin ligand antibodies in a subject, to purify P-selectin ligands and in screening assays to identify molecules which inhibit the interaction of a P-selectin ligand molecule with a P-selectin molecule.

25 Preferably, a PSGL-1 chimeric or fusion protein used in the methods of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-
30 in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently
35 be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion

moiety (e.g., a GST polypeptide). A PSGL-1-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the PSGL-1 protein.

The present invention also pertains to the use of variants of the PSGL-1 proteins which function as either PSGL-1 agonists (mimetics) or as PSGL-1 antagonists. Variants of the PSGL-1 proteins can be generated by mutagenesis, e.g., discrete point mutation or truncation of a PSGL-1 protein. An agonist of the PSGL-1 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a PSGL-1 protein. An antagonist of a PSGL-1 protein can inhibit one or more of the activities of the naturally occurring form of the PSGL-1 protein by, for example, competitively modulating a PSGL-1-mediated activity of a PSGL-1 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the PSGL-1 protein.

In one embodiment, variants of a PSGL-1 protein which function as either PSGL-1 agonists (mimetics) or as PSGL-1 antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a PSGL-1 protein for PSGL-1 protein agonist or antagonist activity. In one embodiment, a variegated library of PSGL-1 variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of PSGL-1 variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential PSGL-1 sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of PSGL-1 sequences therein. There are a variety of methods which can be used to produce libraries of potential PSGL-1 variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential PSGL-1 sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477).

In addition, libraries of fragments of a PSGL-1 protein coding sequence can be used to generate a variegated population of PSGL-1 fragments for screening and subsequent selection of variants of a PSGL-1 protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a PSGL-1 coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double

stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal
5 fragments of various sizes of the PSGL-1 protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of PSGL-1 proteins. The
10 most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive
15 ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify PSGL-1 variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

The methods of the present invention further include the use of anti-PSGL-1
20 antibodies and anti-P-selectin antibodies. An isolated PSGL-1 protein, or P-selectin protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind PSGL-1 or P-selectin using standard techniques for polyclonal and monoclonal antibody preparation. A full-length PSGL-1 protein or P-selectin protein can be used or, alternatively, antigenic peptide fragments of PSGL-1 or P-selectin can be used as
25 immunogens (Johnston *et al.* *Cell* 56 : 1033-1044 1989). The antigenic peptide of PSGL-1 comprises at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2 and encompasses an epitope of PSGL-1 such that an antibody raised against the peptide forms a specific immune complex with the PSGL-1 protein. Preferably, the antigenic peptide comprises at least 10 amino acid residues, more preferably at least 15 amino acid
30 residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

Preferred epitopes encompassed by the antigenic peptide are regions of PSGL-1 that are located on the surface of the protein, *e.g.*, hydrophilic regions, as well as regions with high antigenicity.

35 A PSGL-1 or P-selectin immunogen is typically used to prepare antibodies by immunizing a suitable subject, (*e.g.*, rabbit, goat, mouse, or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed PSGL-1 protein or P-selectin protein or a chemically synthesized

PSGL-1 or P-selectin polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent.

Immunization of a suitable subject with an immunogenic PSGL-1 preparation induces a polyclonal anti-PSGL-1 or anti-P-selectin antibody response.

5 The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site which specifically binds (immunoreacts with) an antigen, such as a PSGL-1 or P-selectin. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab')₂ fragments which can be generated by treating the
10 antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind PSGL-1 molecules. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of PSGL-1. A monoclonal antibody composition
15 thus typically displays a single binding affinity for a particular PSGL-1 protein with which it immunoreacts.

 Polyclonal anti-PSGL-1 antibodies can be prepared as described above by immunizing a suitable subject with a PSGL-1 immunogen. The anti-PSGL-1 antibody titer in the immunized subject can be monitored over time by standard techniques, such as with
20 an enzyme linked immunosorbent assay (ELISA) using immobilized PSGL-1. If desired, the antibody molecules directed against PSGL-1 can be isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, *e.g.*, when the anti-PSGL-1 antibody titers are highest, antibody-producing cells can be obtained
25 from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) *Nature* 256:495-497) (see also, Brown *et al.* (1981) *J. Immunol.* 127:539-46; Brown *et al.* (1980) *J. Biol. Chem.* 255:4980-83; Yeh *et al.* (1976) *Proc. Natl. Acad. Sci. USA* 76:2927-31; and Yeh *et al.* (1982) *Int. J. Cancer* 29:269-75), the more recent human B cell hybridoma
30 technique (Kozbor *et al.* (1983) *Immunol Today* 4:72), the EBV-hybridoma technique (Cole *et al.* (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known (see generally Kenneth, R. H. in *Monoclonal Antibodies: A New Dimension In Biological Analyses*, Plenum Publishing Corp., New York, New York (1980); Lerner, E. A.
35 (1981) *Yale J. Biol. Med.* 54:387-402; Gefter, M. L. *et al.* (1977) *Somatic Cell Genet.* 3:231-36). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a PSGL-1 immunogen as described

above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds PSGL-1.

Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-PSGL-1 monoclonal antibody (see, *e.g.*, G. Galfre *et al.* (1977) *Nature* 266:55052; Gefter *et al.* (1977) *supra*; Lerner (1981) *supra*; and Kenneth (1980) *supra*). Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (*e.g.*, a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, *e.g.*, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind PSGL-1, *e.g.*, using a standard ELISA assay.

Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-PSGL-1 antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (*e.g.*, an antibody phage display library) with PSGL-1 to thereby isolate immunoglobulin library members that bind PSGL-1. Kits for generating and screening phage display libraries are commercially available (*e.g.*, the Pharmacia *Recombinant Phage Antibody System*, Catalog No. 27-9400-01; and the Stratagene *SurfZAP™ Phage Display Kit*, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* PCT International Publication No. WO 92/18619; Dower *et al.* PCT International Publication No. WO 91/17271; Winter *et al.* PCT International Publication WO 92/20791; Markland *et al.* PCT International Publication No. WO 92/15679; Breitling *et al.* PCT International Publication WO 93/01288; McCafferty *et al.* PCT International Publication No. WO 92/01047; Garrard *et al.* PCT International Publication No. WO 92/09690; Ladner *et al.* PCT International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum. Antibod. Hybridomas* 3:81-85; Huse *et al.* (1989)

- Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J. Mol. Biol.* 226:889-896; Clarkson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580; Garrad *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc. Acid Res.* 19:4133-4137; Barbas *et al.* (1991) *Proc. Natl. Acad. Sci. USA* 88:7978-7982; and McCafferty *et al.* (1990) *Nature* 348:552-554.

- Additionally, recombinant anti-PSGL-1 antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the methods of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in Robinson *et al.* International Application No. PCT/US86/02269; Akira, *et al.* European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison *et al.* European Patent Application 173,494; Neuberger *et al.* PCT International Publication No. WO 86/01533; Cabilly *et al.* U.S. Patent No. 4,816,567; Cabilly *et al.* European Patent Application 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:3439-3443; Liu *et al.* (1987) *J. Immunol.* 139:3521-3526; Sun *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:214-218; Nishimura *et al.* (1987) *Canc. Res.* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988) *J. Natl. Cancer Inst.* 80:1553-1559; Morrison, S. L. (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; Winter U.S. Patent 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoeyan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J. Immunol.* 141:4053-4060.

- An anti-PSGL-1 antibody can be used to detect PSGL-1 protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the PSGL-1 protein. Anti-PSGL-1 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

II. Isolated Nucleic Acid Molecules Used in the Methods of the Invention

The coding sequence of the isolated human PSGL-1 cDNA and the amino acid sequence of the human PSGL-1 polypeptide are shown in SEQ ID NOs:1 and 2, respectively. The PSGL-1 sequence is also described in U.S. Patent Numbers 5,827,817, 5,840,679, and 5,843,707, the contents of which are incorporated herein by reference.

The methods of the invention include the use of isolated nucleic acid molecules that encode PSGL-1 proteins or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes to identify PSGL-1-encoding nucleic acid molecules (e.g., PSGL-1 mRNA) and fragments for use as PCR primers for the amplification or mutation of PSGL-1 nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

A nucleic acid molecule used in the methods of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO:1 as a hybridization probe, PSGL-1 nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence of SEQ ID NO:1.

A nucleic acid used in the methods of the invention can be amplified using cDNA, mRNA or, alternatively, genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. Furthermore, oligonucleotides corresponding to PSGL-1 nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

In a preferred embodiment, the isolated nucleic acid molecules used in the methods of the invention comprise the nucleotide sequence shown in SEQ ID NO:1, a complement of the nucleotide sequence shown in SEQ ID NO:1, or a portion of any of these nucleotide sequences. A nucleic acid molecule which is complementary to the nucleotide sequence shown in SEQ ID NO:1, is one which is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1 such that it can hybridize to the nucleotide sequence shown in SEQ ID NO:1 thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule used in the methods of the present invention comprises a nucleotide sequence which is at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to the entire length of the nucleotide sequence shown in SEQ ID NO:1 or a portion of any of
5 this nucleotide sequence.

Moreover, the nucleic acid molecules used in the methods of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO:1, for example, a fragment which can be used as a probe or primer or a fragment encoding a portion of a PSGL-1 protein, *e.g.*, a biologically active portion of a PSGL-1 protein. The probe/primer
10 typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense sequence of SEQ ID NO:1 of an anti-sense sequence of SEQ ID NO:1 or of a naturally occurring allelic variant or mutant of SEQ ID
15 NO:1. In one embodiment, a nucleic acid molecule used in the methods of the present invention comprises a nucleotide sequence which is greater than 100, 100-200, 200-300, 300-400, 400-500, 500-600, 600-700, 700-800, 800-900, 900-1000, 1000-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, or more nucleotides in length and hybridizes under stringent hybridization conditions to a nucleic acid molecule of SEQ ID
20 NO:1.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences that are significantly identical or homologous to each other remain hybridized to each other. Preferably, the conditions are such that sequences at least about 70%, more preferably at
25 least about 80%, even more preferably at least about 85% or 90% identical to each other remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, Inc. (1995), sections 2, 4 and 6. Additional stringent conditions can be found in *Molecular Cloning: A Laboratory Manual*, Sambrook *et al.*, Cold Spring Harbor
30 Press, Cold Spring Harbor, NY (1989), chapters 7, 9 and 11. A preferred, non-limiting example of stringent hybridization conditions includes hybridization in 4X sodium chloride/sodium citrate (SSC), at about 65-70°C (or hybridization in 4X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 1X SSC, at about 65-70°C. A preferred, non-limiting example of highly stringent hybridization conditions includes
35 hybridization in 1X SSC, at about 65-70°C (or hybridization in 1X SSC plus 50% formamide at about 42-50°C) followed by one or more washes in 0.3X SSC, at about 65-70°C. A preferred, non-limiting example of reduced stringency hybridization conditions includes hybridization in 4X SSC, at about 50-60°C (or alternatively hybridization in 6X

SSC plus 50% formamide at about 40-45°C) followed by one or more washes in 2X SSC, at about 50-60°C. Ranges intermediate to the above-recited values, *e.g.*, at 65-70°C or at 42-50°C are also intended to be encompassed by the present invention. SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC

5 (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes each after hybridization is complete. The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in

10 length, $T_m(^{\circ}\text{C}) = 2(\# \text{ of A + T bases}) + 4(\# \text{ of G + C bases})$. For hybrids between 18 and 49 base pairs in length, $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\% \text{G+C}) - (600/\text{N})$, where N is the number of bases in the hybrid, and $[\text{Na}^+]$ is the concentration of sodium ions in the hybridization buffer ($[\text{Na}^+]$ for 1xSSC = 0.165 M). It will also be recognized by the skilled practitioner that additional reagents may be added to hybridization and/or wash buffers to

15 decrease non-specific hybridization of nucleic acid molecules to membranes, for example, nitrocellulose or nylon membranes, including but not limited to blocking agents (*e.g.*, BSA or salmon or herring sperm carrier DNA), detergents (*e.g.*, SDS), chelating agents (*e.g.*, EDTA), Ficoll, PVP and the like. When using nylon membranes, in particular, an additional preferred, non-limiting example of stringent hybridization conditions is hybridization in

20 0.25-0.5M NaH₂PO₄, 7% SDS at about 65°C, followed by one or more washes at 0.02M NaH₂PO₄, 1% SDS at 65°C, see *e.g.*, Church and Gilbert (1984) *Proc. Natl. Acad. Sci. USA* 81:1991-1995, (or alternatively 0.2X SSC, 1% SDS).

In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or

25 an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a PSGL-1 protein, such as by measuring a level of a PSGL-1-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting PSGL-1 mRNA levels or determining whether a genomic PSGL-1 gene has been mutated or deleted.

30 The methods of the present invention may use non-human orthologues of the human PSGL-1 protein. Orthologues of the human PSGL-1 protein are proteins that are isolated from non-human organisms and possess the same PSGL-1 activity.

The methods of the present invention further include the use of nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO:1 or a portion thereof, in

35 which a mutation has been introduced. The mutation may lead to amino acid substitutions at "non-essential" amino acid residues or at "essential" amino acid residues. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of PSGL-1 (*e.g.*, the sequence of SEQ ID NO:2) without altering the biological activity,

whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues comprising fragments which are capable of interacting with P-selectin or which are capable of inhibiting P-selectin-mediated intercellular adhesion or cellular migration are not likely to be amenable to alteration.

5 Mutations can be introduced into SEQ ID NO:1 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues
10 having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine,
15 valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a PSGL-1 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a PSGL-1 coding sequence, such as by saturation mutagenesis, and the resultant
20 mutants can be screened for PSGL-1 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:1 the encoded protein can be expressed recombinantly and the activity of the protein can be determined using the assay described herein.

 Given the coding strand sequences encoding PSGL-1 disclosed herein, antisense
25 nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of PSGL-1 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of PSGL-1 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the
30 translation start site of PSGL-1 mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring
35 nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate

the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

In yet another embodiment, the PSGL-1 nucleic acid molecules used in the methods of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4 (1): 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* (1996) *Proc. Natl. Acad. Sci.* 93:14670-675.

PNAs of PSGL-1 nucleic acid molecules can be used in the therapeutic and diagnostic applications described herein. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of PSGL-1 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (*e.g.*, by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (*e.g.*, S1 nucleases (Hyrup B. *et al.* (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *et al.* (1996) *supra*).

In another embodiment, PNAs of PSGL-1 can be modified, (*e.g.*, to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of PSGL-1 nucleic acid

5 molecules can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (*e.g.*, RNase H and DNA polymerases), to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the

10 nucleobases, and orientation (Hyrup B. *et al.* (1996) *supra*). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup B. *et al.* (1996) *supra* and Finn P.J. *et al.* (1996) *Nucleic Acids Res.* 24 (17): 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite,

15 can be used as a between the PNA and the 5' end of DNA (Mag, M. *et al.* (1989) *Nucleic Acid Res.* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment (Finn P.J. *et al.* (1996) *supra*). Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment (Peterser, K.H. *et al.* (1975) *Bioorganic Med. Chem. Lett.* 5: 1119-11124).

20 In other embodiments, the oligonucleotide used in the methods of the invention may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see,

25 *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (See, *e.g.*, Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (*e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

30

III Recombinant Expression Vectors and Host Cells Used in the Methods of the Invention

The methods of the invention (*e.g.*, the screening assays described herein) include the use of vectors, preferably expression vectors, containing a nucleic acid encoding a

35 PSGL-1 protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector,

wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors to be used in the methods of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel (1990) *Methods Enzymol.* 185:3-7. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (*e.g.*, PSGL-1 proteins, mutant forms of PSGL-1 proteins, fusion proteins, and the like).

The recombinant expression vectors to be used in the methods of the invention can be designed for expression of P-selectin ligand proteins in prokaryotic or eukaryotic cells. For example, PSGL-1 proteins can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors), yeast cells, or mammalian cells. Suitable host cells are discussed further in Goeddel (1990) *supra*. Alternatively, the recombinant expression

vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be utilized in PSGL-1 activity assays, (*e.g.*, direct assays or competitive assays described in detail below), or to generate antibodies specific for PSGL-1 proteins.

In another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J. *et al.*, *Molecular Cloning: A Laboratory Manual. 2nd ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid).

The methods of the invention may further use a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to PSGL-1 mRNA. Regulatory sequences

operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific, or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid, or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes, see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to the use of host cells into which a PSGL-1 nucleic acid molecule of the invention is introduced, *e.g.*, a PSGL-1 nucleic acid molecule within a recombinant expression vector or a PSGL-1 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a PSGL-1 protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

A host cell used in the methods of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) a PSGL-1 protein. Accordingly, the invention further provides methods for producing a PSGL-1 protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of the invention (into which a recombinant expression vector encoding a PSGL-1 protein has been

introduced) in a suitable medium such that a PSGL-1 protein is produced. In another embodiment, the method further comprises isolating a PSGL-1 protein from the medium or the host cell.

5 IV. Methods of Treatment or Prevention of Restenosis and Stenosis:

The present invention provides for both prophylactic and therapeutic methods of treating a subject, *e.g.*, a human, at risk of (or susceptible to) stenosis or restenosis, including constrictive vascular remodeling and neointimal formation, as a result of vascular injury, *e.g.* injury from PTCA (restenosis) or pathologic injury, *e.g.*, cardiovascular disease
10 (stenosis). With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics," as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term
15 refers to the study of how a patient's genes determine his or her response to a drug (*e.g.*, a patient's "drug response phenotype", or "drug response genotype").

Thus, another aspect of the invention provides methods for tailoring a subject's prophylactic or therapeutic treatment with either the P-selectin antagonists of the present invention or P-selectin ligand modulators according to that individual's drug response
20 genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

A. Prophylactic And Therapeutic Methods

25 In one aspect, the invention provides a method for modulating, *e.g.*, inhibiting, stenosis or restenosis in a subject by administering to the subject an agent which modulates PSGL-1 expression or PSGL-1 activity, *e.g.*, modulates P-selectin binding, modulates intercellular adhesion, *e.g.*, platelet-leukocyte adhesion and endothelial-leukocyte adhesion, or modulates cell migration, *e.g.*, leukocyte recruitment to platelets and endothelial cells,
30 modulates restenosis, modulates vascular remodeling, and modulates neointimal formation. Subjects at risk for stenosis or restenosis can be identified by, for example, any or a combination of the diagnostic or prognostic assays described herein. In particular, subjects at risk for stenosis are those individuals who suffer from cardiovascular disease. Subjects who are at risk for restenosis include those who are undergoing cardiovascular and general
35 vascular procedures or intervention such as surgical revascularization, stenting, PCTA or other intervention, surgical or non-surgical, which causes vascular injury.

Cardiovascular diseases and disorders which place a subject at risk for stenosis and make them a target for treatment with the P-selectin antagonists of the invention include

arteriosclerosis, ischemia reperfusion injury, arterial inflammation, rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, pressure overload, aortic bending, vascular heart disease, atrial fibrillation, Jervell syndrome, Lange-Nielsen syndrome, long-QT syndrome, congestive heart failure, sinus node dysfunction, angina, heart failure, hypertension, atrial fibrillation, atrial flutter, cardiomyopathy, *e.g.*, dilated cardiomyopathy and idiopathic cardiomyopathy, myocardial infarction, coronary artery disease, coronary artery spasm, and arrhythmia.

Administration of a prophylactic or therapeutic agent, *e.g.*, an anti-P-selectin antibody, an anti-P-selectin ligand antibody, or soluble P-selectin ligand, can occur prior to the manifestation of restenosis or stenosis, or prior to the introduction of vascular injury, such that restenosis or stenosis is inhibited or, alternatively, delayed in its progression, and positive vascular remodeling post-intervention is effectuated. In addition, the agent may be administered to a subject with prior vascular injury caused by vascular or cardiovascular disease who is undergoing vascular intervention resulting in further vascular injury.

Methods of administering to a subject a P-selectin antagonist, *e.g.*, an anti-P-selectin antibody, an anti-P-selectin ligand antibody, soluble P-selectin ligand, soluble PSGL-1 or soluble rPSGL-Ig, to prevent or treat restenosis and positively impact vascular remodeling, include, but are not limited to, the following methods. The soluble P-selectin antagonists of the invention can be administered to a subject using pharmaceutical compositions suitable for such administration. Such compositions typically comprise the agent (*e.g.*, protein or antibody) and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition used in the therapeutic methods of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as

sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous
5 solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under
10 the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as
15 lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, and sodium chloride in the
20 composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the agent that modulates PSGL-1 activity (*e.g.*, a fragment of a soluble PSGL-1 protein) in the required amount in an
25 appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are
30 vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral
therapeutic administration, the active compound can be incorporated with excipients and
35 used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The

tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The agents that modulate PSGL-1 activity can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the agents that modulate PSGL-1 activity are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the agent that modulates PSGL-1 activity

and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an agent for the treatment of subjects.

Toxicity and therapeutic efficacy of such agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the
5 LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. Agents which exhibit large therapeutic indices are preferred. While agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of
10 affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such PSGL-1 modulating agents lies preferably within a range of circulating concentrations that include the ED50
15 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any agent used in the therapeutic methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the
20 test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of protein or polypeptide (*i.e.*,
25 an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of
30 the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

In a preferred example, a subject is treated with antibody, protein, or polypeptide in
35 the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of antibody, protein, or polypeptide used for treatment may increase or

decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such small molecules
5 include, but are not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (*i.e.*, including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic
10 compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds. It is understood that appropriate doses of small molecule agents depends upon a number of factors within the ken of the ordinarily skilled physician, veterinarian, or researcher. The
15 dose(s) of the small molecule will vary, for example, depending upon the identity, size, and condition of the subject or sample being treated, further depending upon the route by which the composition is to be administered, if applicable, and the effect which the practitioner desires the small molecule to have upon the nucleic acid or polypeptide of the invention. Exemplary doses include milligram or microgram amounts of the small molecule per
20 kilogram of subject or sample weight (*e.g.*, about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram). It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. Such
25 appropriate doses may be determined using the assays described herein. When one or more of these small molecules is to be administered to an animal (*e.g.*, a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition,
30 it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

35 Further, an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a therapeutic agent or a radioactive metal ion. Therapeutic agents include, but are not limited to, antimetabolites (*e.g.*, methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (*e.g.*, mechlorethamine, thioepa

chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (*e.g.*, daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (*e.g.*, dactinomycin (formerly actinomycin), bleomycin, 5 mithramycin, and anthramycin (AMC)), and anti-mitotic agents (*e.g.*, vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired 10 biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, alpha-interferon, beta-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte 15 macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, *e.g.*, Arnon *et al.*, "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld *et al.* (eds.), pp. 243-56 20 (Alan R. Liss, Inc. 1985); Hellstrom *et al.*, "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson *et al.* (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera *et al.* (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of 25 Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin *et al.* (eds.), pp. 303-16 (Academic Press 1985), and Thorpe *et al.*, "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.*, 62:119-58 (1982). Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 30 4,676,980.

The nucleic acid molecules used in the methods of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see, *e.g.*, Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054- 35 3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector

can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

B. Pharmacogenomics

5 In conjunction with the therapeutic methods of the invention, pharmacogenomics (*i.e.*, the study of the relationship between a subject's genotype and that subject's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician
10 may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a P-selectin antagonist, *e.g.*, soluble PSGL-1, as well as tailoring the dosage and/or therapeutic regimen of treatment with an agent which modulates PSGL-1 activity.

Pharmacogenomics deals with clinically significant hereditary variations in the
15 response to drugs due to altered drug disposition and abnormal action in affected persons. See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23(10-11): 983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic
20 conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate aminopeptidase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides,
25 analgesics, nitrofurans) and consumption of fava beans.

One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (*e.g.*, a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human
30 genome, each of which has two variants). Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common alteration that occurs
35 in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of

such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

5 Alternatively, a method termed the "candidate gene approach" can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug target is known (*e.g.*, a PSGL-1 protein of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

10 As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and the cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response
15 and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor
20 metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently,
25 the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

 Alternatively, a method termed the "gene expression profiling" can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (*e.g.*, a PSGL-1 molecule or P-selectin antagonist of the present
30 invention) can give an indication whether gene pathways related to toxicity have been turned on.

 Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment of a subject. This knowledge, when applied to dosing
35 or drug selection, can avoid adverse reactions or therapeutic failure and, thus, enhance therapeutic or prophylactic efficiency when treating or preventing restenosis or stenosis with an agent which modulates PSGL-1 activity.

V. Screening Assays:

The invention provides methods (also referred to herein as "screening assays") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules, ribozymes, or PSGL-1 antisense molecules) which bind to PSGL-1 proteins, have a stimulatory or inhibitory effect on PSGL-1 expression or PSGL-1 activity, or have a stimulatory or inhibitory effect on the expression or activity of a PSGL-1 target molecule, *e.g.* P-selectin, or have an effect, *e.g.*, inhibition of cellular migration or adhesion, on cells expressing a PSGL-1 target molecule, *e.g.*, endothelial cells and platelets. Compounds identified using the assays described herein may be useful for modulating stenosis and restenosis, constrictive vascular remodeling, neointimal formation, and cell adhesion and migration.

Candidate/test compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, *e.g.*, Lam, K.S. et al. (1991) *Nature* 354:82-84; Houghten, R. et al. (1991) *Nature* 354:84-86) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2) phosphopeptides (*e.g.*, members of random and partially degenerate, directed phosphopeptide libraries, see, *e.g.*, Songyang, Z. et al. (1993) *Cell* 72:767-778); 3) antibodies (*e.g.*, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (*e.g.*, molecules obtained from combinatorial and natural product libraries).

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann et al. (1994) *J. Med. Chem.* 37:2678; Cho et al. (1993) *Science* 261:1303; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell et al. (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop et al. (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409),

plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici (1991) *J. Mol. Biol.* 222:301-310; Ladner *supra.*).

- 5 Assays that may be used to identify compounds that modulate PSGL-1 activity and P-selectin activity include assays for cell adhesion using ^{51}Cr -labelled cells, *e.g.*, leukocytes (as described in, for example, Kennedy *et al* (2000) *Br J Pharmacology* 130(1):95), and assays for cell migration, *e.g.*, platelet, neutrophil and leukocyte migration (as described in, for example Kogaki *et al.* (1999) *Cardiovascular Res* 43(4):968) and Bengtsson *et al.*
10 (1999) *Scand J Clin Lab Invest* 59(6):439).

 In one aspect, an assay is a cell-based assay in which a cell which expresses a PSGL-1 protein or biologically active portion of the PSGL-1 protein that is believed to be involved in the binding of P-selectin (*e.g.*, amino acid residues 42 to 60 of SEQ ID NO:2) is contacted with a test compound, and the ability of the test compound to modulate PSGL-1
15 activity is determined. In a preferred embodiment, the biologically active portion of the PSGL-1 protein includes a domain or motif that is capable of interacting with P-selectin or inhibiting P-selectin mediated intercellular adhesion. Determining the ability of the test compound to modulate PSGL-1 activity can be accomplished by monitoring, for example, cell adhesion or cell migration. The cell, for example, can be of mammalian origin, *e.g.*, an
20 endothelial cell, or a leukocyte.

 The ability of the test compound to modulate PSGL-1 binding to a substrate or to bind to PSGL-1 can also be determined. Determining the ability of the test compound to modulate PSGL-1 binding to a substrate can be accomplished, for example, by coupling the PSGL-1 substrate with a radioisotope or enzymatic label such that binding of the PSGL-1
25 substrate to PSGL-1 can be determined by detecting the labeled PSGL-1 substrate in a complex. Alternatively, PSGL-1 could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate PSGL-1 binding to a PSGL-1 substrate in a complex. Determining the ability of the test compound to bind PSGL-1 can be accomplished, for example, by coupling the compound with a radioisotope or enzymatic
30 label such that binding of the compound to PSGL-1 can be determined by detecting the labeled PSGL-1 compound in a complex. For example, PSGL-1 substrates can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline
35 phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

 It is also within the scope of this invention to determine the ability of a compound to interact with PSGL-1 without the labeling of any of the interactants. For example, a

microphysiometer can be used to detect the interaction of a compound with PSGL-1 without the labeling of either the compound or the PSGL-1 (McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912). As used herein, a "microphysiometer" (*e.g.*, Cytosensor) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and PSGL-1.

In yet another embodiment, an assay of the present invention is a cell-free assay in which a PSGL-1 protein or biologically active portion thereof (*e.g.*, a fragment of a PSGL-1 protein which is capable of binding P-selectin) is contacted with a test compound and the ability of the test compound to bind to or to modulate (*e.g.*, stimulate or inhibit) the activity of the PSGL-1 protein or biologically active portion thereof is determined. Preferred biologically active portions of the PSGL-1 proteins to be used in assays of the present invention include fragments which participate in interactions with non-PSGL-1 molecules, *e.g.*, fragments with high surface probability scores. Binding of the test compound to the PSGL-1 protein can be determined either directly or indirectly as described above. Determining the ability of the PSGL-1 protein to bind to a test compound can also be accomplished using a technology such as real-time Biomolecular Interaction Analysis (BIA) (Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345; Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705). As used herein, "BIA" is a technology for studying biospecific interactions in real time, without labeling any of the interactants (*e.g.*, BIAcore). Changes in the optical phenomenon of surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either PSGL-1 or P-selectin to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a PSGL-1 protein, or interaction of a PSGL-1 protein with P-selectin in the presence and absence of a test compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/PSGL-1 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or PSGL-1 protein, and the mixture incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix is immobilized in the case of beads,

and complex formation is determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of PSGL-1 binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either a PSGL-1 protein or a P-selectin molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated PSGL-1 protein or P-selectin protein can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which are reactive with PSGL-1 protein or P-selectin but which do not interfere with binding of the PSGL-1 protein to its target molecule can be derivatized to the wells of the plate, and unbound target or PSGL-1 protein is trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the PSGL-1 protein or P-selectin, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the PSGL-1 protein or P-selectin.

In yet another aspect of the invention, the PSGL-1 protein or fragments thereof (e.g., a fragment capable of binding P-selectin) can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with PSGL-1 ("PSGL-1-binding proteins" or "PSGL-1-bp) and are involved in PSGL-1 activity. Such PSGL-1-binding proteins are also likely to be involved in the propagation of signals by the PSGL-1 proteins or PSGL-1 targets as, for example, downstream elements of a PSGL-1-mediated signaling pathway. Alternatively, such PSGL-1-binding proteins are likely to be PSGL-1 inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a PSGL-1 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a PSGL-1-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a

transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the PSGL-1 protein.

5 In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-based or a cell-free assay, and the ability of the agent to modulate the activity of a P-selectin ligand antagonist can be confirmed *in vivo*, *e.g.*, in an animal such as an animal model for cardiovascular disease. Other examples of animals that may be used include non-
10 recombinant, non-genetic animal models of restenosis or constrictive vascular remodeling such as, for example, rabbit, mouse, porcine, or rat models in which the animal has been subjected to vascular injury, *e.g.*, balloon angioplasty, (as described in Razavi *et al* (1999) *Int J Radiat Oncol Biol Phys* 44(2):363-7), injection of a photoactive dye, *e.g.*, rose bengal, (as described in Trieu *et al*(2000) *J Cardiovasc Pharmacol* 35(4):595-605), coronary stents
15 (as described in Baumbach *et al* (2000) *Basic Res Cardiol* 95(3):173-8), or vascular ligation (as described in Kumar *et al* (1997) *Artheroscler Thromb Vasc Biol.* 17:2238). The extent of modulation of restenosis and vascular remodeling can be measured, for example, by morphological analysis of the cardiovascular vessels prior to vascular injury and post-vascular injury. PSGL-1 and P-selectin modulators can be identified where there has been
20 positive vascular remodeling (*e.g.*, lack of constrictive remodeling) and modulation of restenosis (*e.g.* prevention, inhibition or treatment).

Moreover, a PSGL-1 modulator identified as described herein (*e.g.*, an antisense PSGL-1 nucleic acid molecule, a PSGL-1-specific antibody, or a small molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with
25 such a modulator. Alternatively, a PSGL-1 modulator identified as described herein can be used in an animal model to determine the mechanism of action of such a modulator.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent
30 applications cited throughout this application, as well as the Figures and the Sequence Listing is incorporated herein by reference.

EXAMPLES

35 EXAMPLE 1: CONSTRUCTION OF SOLUBLE P-SELECTIN LIGANDS

The EcoRI adaptors used to generate the cDNA library from HL60 cells in Example I contain an XbaI restriction site (TCTAGA) (SEQ ID NO:3) just 5' of the beginning of SEQ

ID NO:1 as it is located in the pMT21:PL85 plasmid. In order to generate soluble forms of the PSL, the pMT21:PL85 plasmid was restricted with XbaI and with HincII (which cleaves after nucleotide 944 of SEQ ID NO:1). The approximately 950 bp fragment thus generated, containing all of the encoded extracellular segment of the ligand up to and including the
5 codon for valine 295, was isolated and used to generate DNAs encoding soluble forms of the P-selectin ligand protein as set forth in sections A through D below.

A. Construction of psPSL.QC

10 The fragment was purified and ligated into mammalian expression vector pED between the XbaI and EcoRI sites, along with double stranded synthetic oligonucleotide DNA that recreated the codons from Asn 296 to Cys 310 and introduced a novel stop codon immediately following Cys 310. The sequence of the oligos is as follows:

15 5'-AACTACCCAGTGGGAGCACCAGACCACATCTCTGTGAAGCAGTGCTAG (SEQ ID NO:4)

5'-AATTCTAGCACTGCTTCACAGAGATGTGGTCTGGTGCTCCCACTGGGTAGTT (SEQ ID NO:5)

20 The resulting plasmid was designated pED.sPSL.QC, and the protein expressed from the plasmid was designated sPSL.QC.

B. Construction of psPSL.Q

25 The fragment was purified and ligated into the pED plasmid (Kaufman et al., 1991) between the XbaI and EcoRI sites, along with the double stranded synthetic oligonucleotide DNA that recreated the codons from Asn 296 to Gln 309 and introduced a novel stop codon immediately following Gln 309. The sequence of the oligos is as follows:

30 5'-AACTACCCAGTGGGAGCACCAGACCACATCTCTGTGAAGCAGTAG (SEQ ID NO:6)

5'-AATTCTACTGCTTCACAGAGATGTGGTCTGGTGCTCCCACTGGGTAGTT (SEQ ID NO:7)

35

The resulting plasmid was designated pED.sPSL.Q, and the protein expressed from the plasmid was designated sPSL.Q.

C. Construction of psPSL.T7

Oligonucleotides encoding 14 amino acids including an epitope derived from the
5 phage T7 major capsid protein were synthesized, creating a C-terminal fusion of the epitope
"tag" with an additional 32 amino acids derived from the vector sequence. Two
oligonucleotides having the sequences:

5'-CTAGACCCGGGATGGCATCCATGACAGGAGGACAACAAATGGTAGGCCGTAG
10 (SEQ ID NO:8); and

5'-AATTCTACGGCCTACCCATTTGTTGTCCTCCTGTCATGGATGCCATCCCGGGT
(SEQ ID NO:9)

15 were duplexed and ligated with the large XbaI-EcoRI fragment of mammalian expression
plasmid pED. The resulting plasmid, pED.T7 was restricted with XbaI and SmaI and
ligated to the 950 bp XbaI-HincII fragment described above, resulting in plasmid
pED.sPSL.T7.

The protein resulting from expression of pED.sPSL.T7 was designated sPSL.T7.
20

D. Construction of Soluble P-selectin Ligand-IgGFc Chimera

The plasmid DNA encoding a soluble, extracellular form of the P-selectin ligand
protein fused to the Fc portion of human immunoglobulin IgG1 was constructed as follows:
the mammalian expression vector pED.Fc contains sequences encoding the Fc region of a
25 human IgG1 with a novel linker sequence enabling the fusion of coding sequences amino
terminal to the hinge region via a unique XbaI restriction site. A three fragment ligation was
performed: pED.Fc was restricted with XbaI and gel purified in linear form. The 950 bp
fragment from pMT21:PL85 described above comprised the second fragment. The third
fragment consisted of annealed synthetic oligonucleotide DNAs having the following
30 sequence:

5'-CTGCGGCCGCAGT (SEQ ID NO:10)

5'-CTAGACTGCGGCCGCAG (SEQ ID NO:11)
35

The ligation products were grown as plasmid DNAs and individual clones having the
correct configuration were identified by DNA sequencing. The plasmid was designated

pED.PSL.Fc. The DNA coding region of the resulting soluble P-selectin ligand/Fc fusion protein is shown in SEQ ID NO:12.

**EXAMPLE 2: EFFECT OF SOLUBLE P-SELECTIN GLYCOPROTEIN LIGAND-1
5 CHIMERA ON RESTENOSIS FOLLOWING ARTERIAL INJURY BY REPEAT
ANGIOPLASTY IN PIGS**

This example describes the effect of a soluble P-selectin glycoprotein ligand-1 (PSGL-1) chimera (rPSGL-Ig) on restenosis following arterial injury by repeat carotid
10 angioplasty. The repeat carotid injury model is a clinically relevant double injury model in which the first angioplasty creates damage to the vessel similar to the vascular injury caused by vascular intervention or from a cardiovascular disease or disorder. rPSGL-Ig is a recombinant soluble form of PSGL-1 fused to a human IgG (see Example 1D).

Crossbred Yorkshire swine (15-20 kg in weight) were used in the following
15 experiment. Angioplasty of the common carotid arteries using a 7F balloon dilated at 6 atm was performed on both carotid arteries of the pigs used in the experiment. Angiographic measurements of carotid arteries diameter and of balloon/artery ratio were taken. The animals were then allowed to recover for a period of four weeks, during which time neointimal lesions developed at injury sites. Repeat angioplasty at the same sites was then
20 performed 15 minutes after a single administration of either a vehicle (formulation buffer), or rPSGL-1-Ig (1 mg/kg, IV, with a half life of 10 days in pigs). Twenty-three animals received the vehicle and 17 animals received rPSGL-Ig just prior to the second angioplasty. Following the second angioplasty, autologous ⁵¹Cr-platelets and ¹¹¹In-neutrophils were radioactively labeled and injected. The animals were sacrificed at 1 hour, 4 hours, 1 week,
25 or 4 weeks following the second angioplasty. Each animal was euthanized under anesthesia with *in situ* perfusion of carotid arteries.

After the animals were euthanized, a macroscopic examination of dilated and non-dilated carotid arterial segments was performed and ⁵¹Cr-platelet and ¹¹¹In-neutrophil
adhesion to arterial segments were quantified using a gama counter. Immunohistochemical
30 detection of P-selection and morphometric analysis of histological arterial sections were also performed to assess restenosis.

Blood sampling, angiograms, ⁵¹Cr-platelet and ¹¹¹In-neutrophil injections were carried out at 1 hr, 4 hrs, 1 week, and 4 weeks after the second angioplasty. Blood sampling and angiograms were also carried out after the first angioplasty of carotid arteries, prior to
35 the second angioplasty, and at the second angioplasty. An evaluation of hematological parameters, hemodynamic parameters, activated clotting time (ACT), and platelet aggregation in whole blood after ADP (10 uM) stimulation, was performed in the animals before treatment with the vehicle or rPSGL-Ig and after treatment with the vehicle or

rPSGL-1. The hematological and hemodynamic parameters in control and rPSGL-Ig treated animals are illustrated in Table 1, below.

Table 1.

Parameters	Vehicle		rPSGL-Ig	
	Before	After	Before	After
Number of Animals	23	23	17	17
Leukocytes ($\times 10^6/\text{mL}$)	19.9 ± 1.3	19.2 ± 1.3	21.7 ± 2.0	20.7 ± 2.1
Neutrophils (%)	53.3 ± 4.0	53.5 ± 3.9	53.6 ± 3.7	58.4 ± 3.4
Platelets ($\times 10^6/\text{mL}$)	427 ± 22	423 ± 23	466 ± 31	466 ± 24
Hematocrit (%)	26.6 ± 0.6	25.8 ± 0.6	26.4 ± 0.7	25.9 ± 0.7
Activated clotting time (sec)	117 ± 3	126 ± 5	115 ± 2	$129 \pm 6^*$
Heart rate (bpm)	124 ± 8	129 ± 7	103 ± 8	$114 \pm 8^*$
Mean arterial pressure (mm Hg)	66 ± 3	65 ± 3	58 ± 2	61 ± 2

* $p < 0.05$ vs before, paired student's t-test

Results indicate that rPSGL-Ig reduced adhesion of platelets by 85% (Figure 1) and neutrophils by 75% (Figure 2) in deeply injured arterial segments 1 week following repeat angioplasty.

As shown in Table 2, below, at 4 weeks, the residual lumen in deeply injured segments was 63% larger in the rPSGL-Ig treated pigs as compared to the control (6.1 ± 0.6 vs. $3.8 \pm 0.1 \text{ mm}^2$). The neointimal area in the rPSGL-Ig treated animals was slightly smaller than in the control (0.5 ± 0.1 vs $0.7 \pm 0.1 \text{ mm}^2$). The ratio of the external elastic lamina (EEL) surface in deeply injured to uninjured vessel segments was 1.5 ± 0.1 in the rPSGL-Ig group vs. 0.9 ± 0.05 in the control group ($p < 0.01$) which indicates a positive effect on compensatory remodeling (see Figures 5 and 6).

Table 2.

5	Parameters	Vehicle	rPSGL-Ig
	EEL surface (mm ²)	6.93 ± 0.60	10.55 ± 0.85*
10	<i>Normalized</i>	0.96 ± 0.05	1.51 ± 0.10*
	EEL Length (mm)	9.38 ± 0.40	11.57 ± 0.44*
	<i>Normalized</i>	0.98 ± 0.03	1.18 ± 0.03*
15	IEL surface (mm ²)	4.54 ± 0.60	6.60 ± 0.60*
	<i>Normalized</i>	0.86 ± 0.08	1.34 ± 0.09*
20	IEL length (mm ²)	7.49 ± 0.05	9.18 ± 0.04*
	<i>Normalized</i>	0.91 ± 0.04	1.10 ± 0.03*
	Residual lumen (mm ²)	3.84 ± 0.06	6.08 ± 0.58*
25	<i>Normalized</i>	0.71 ± 0.09	1.22 ± 0.08*
	% vascular stenosis	29.22 ± 9.52	-21.59 ± 8.49*
30	Neointimal surface (mm ²)	0.70 ± 0.09	0.52 ± 0.09
	EEL: External elastic lamina		
	IEL: Internal elastic lamina		
35	<i>Normalized: dilated / reference values</i>		
	* p < 0.005 vs control		

Figure 6 illustrates the remodeling effect of treatment with rPSGL-Ig 4 weeks after the second angioplasty. Treatment with rPSGL-Ig resulted in a larger lumen area and less neointimal formation, as compared to the control artery. Accordingly, treatment with

40 rPSGL-Ig has resulted in the inhibition of restenosis, as compared to the control.

EXAMPLE 3: INHIBITION OF IN-STENT RESTENOSIS AND NEOINTIMAL FORMATION BY SOLUBLE P-SELECTIN GLYCOPROTEIN LIGAND-1 CHIMERA IN PIGS

5 This study describes the inhibition of neointimal formation and restenosis following stenting of coronary arteries after angioplasty.

Coronary angioplasty was performed resulting in injury to the LAD, LCX, and RCA coronary arteries of pigs. Two weeks following initial injury, stents were implanted at the injury-induced lesion site in 2 randomly selected vessels. Six pigs (control animals)
10 received a vehicle (formulation buffer) and five pigs received rPSGL-1 (1 mg/kg). The vehicle and rPSGL-1 were administered as a single IV bolus, 15 minutes before stenting. Four weeks later, adhesion of ^{51}Cr -platelets and ^{111}In -neutrophils was quantified and histomorphologic analysis was performed.

In reference, non-injured artery segments, the vascular lumen was similar in both
15 control (3.0mm^2) and rPSGL-Ig (2.8mm^2) groups. The overall cross sectional area of stented and reference sites was unchanged between groups. However, in-stent residual lumen was reduced significantly by 49% to $1.6 \pm 0.4\text{ mm}^2$ in control, whereas it remained statistically unchanged ($3.2 \pm 0.5\text{ mm}^2$) in rPSGL-Ig treated animals, indicating significant inhibition of restenosis by rPSGL-Ig.

20 Neointimal area as a percentage of total cross sectional area was reduced by rPSGL-Ig treatment (66.7 ± 2.8 vs 52.4 ± 4.9 ; $p < 0.05$). There was a 49% inhibition of neutrophil adhesion ($p < 0.05$), and a 39% reduction of platelet adhesion.

25 **Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed:

1. A method for modulating stenosis or restenosis in a subject having vascular injury or cardiovascular disease, comprising administering a P-selectin antagonist, thereby
5 modulating stenosis or restenosis.
2. The method of claim 1, wherein the P-selectin antagonist comprises a P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity.
- 10 3. The method of claim 1, wherein the P-selectin antagonist comprises a soluble P-selectin ligand protein, or a fragment thereof having P-selectin ligand activity.
4. The method of claim 3, wherein the P-selectin antagonist is soluble PSGL-1.
- 15 5. The method of claim 3, wherein the P-selectin antagonist is soluble rPSGL-Ig.
6. The method of claim 1, wherein the P-selectin antagonist comprises an anti-P-selectin antibody.
- 20 7. The method of claim 1, wherein the P-selectin antagonist comprises an anti-P-selectin ligand antibody.
8. The method of claims 1, wherein the composition comprises a pharmaceutically acceptable carrier.
- 25 9. The method of claim 1, wherein restenosis are characterized by constrictive vascular remodeling.
10. The method of claim 1, wherein restenosis is characterized by neointimal formation.
- 30 11. The method of claim 1, wherein said subject is human.
12. The method of claim 1, wherein said P-selectin antagonist is administered to the subject prior to vascular injury.
- 35 13. The method of claim 1, wherein said vascular injury or cardiovascular disease affects a coronary artery.


14. The method of claim 1, wherein said vascular injury or cardiovascular disease affects a peripheral artery.
15. The method of claim 14, wherein said artery is a carotid artery.
- 5 16. The method of claim 1, wherein said vascular injury results from angioplasty.
17. The method of claim 16, wherein said angioplasty is percutaneous transluminal coronary angioplasty (PTCA).
- 10 18. The method of claim 1, wherein said vascular injury results from implantation of a stent or stents.
19. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 15 42 to amino acid 60.
20. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 20 42 to amino acid 88.
21. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 25 42 to amino acid 118.
22. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 189.
- 30 23. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 310.
- 35 24. The method of claim 3, wherein said protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence set forth in SEQ ID NO:2 from amino acid 42 to amino acid 316.

25. The method of claim 3, wherein said soluble protein comprises an Fc portion of an immunoglobulin.
26. The method of claim 25, wherein said immunoglobulin is human IgG.
- 5 27. The method of claim 3, wherein said soluble protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence from amino acid 42 to amino acid 60 of SEQ ID NO:2 fused at its C-terminus to the Fc portion of an immunoglobulin.
- 10 28. The method of claim 3, wherein said soluble protein comprises a soluble P-selectin ligand protein comprising the amino acid sequence from amino acid 42 to amino acid 88 of SEQ ID NO:2 fused at its C-terminus to the Fc portion of an immunoglobulin.
- 15 29. The method of claim 27 or 28, wherein said amino acid sequence is fused through a linking sequence.
30. A method for modulating leukocyte recruitment in a subject comprising administering soluble PSGL-1, thereby modulating leukocyte recruitment.
- 20 31. A method for modulating leukocyte recruitment in a subject comprising administering an anti-P-selectin ligand antibody, thereby modulating leukocyte recruitment.
32. A method for modulating leukocyte recruitment in a subject comprising administering an anti-P-selectin antibody, thereby modulating leukocyte recruitment.
- 25 33. A method for inhibiting cell to cell adhesion in a subject comprising administering soluble PSGL-1, thereby inhibiting cell to cell adhesion.
34. A method for inhibiting cell to cell adhesion in a subject comprising administering an anti-P-selectin ligand antibody, thereby inhibiting cell to cell adhesion
- 30 35. A method for inhibiting cell to cell adhesion in a subject comprising administering an anti-P-selectin antibody, thereby inhibiting cell to cell adhesion
- 35 36. The method of claim 33, 34, or 35, wherein the adhesive cells are selected from the group consisting of leukocytes, platelets, and endothelial cells.

37. The method of claim 33, 34, or 35, wherein the adhesive cells are leukocytes and platelets.
38. A method for inhibiting cell adhesion to blood vessels in a subject comprising
5 administering soluble PSGL-1, thereby inhibiting cell adhesion to blood vessels.
39. A method for inhibiting cell adhesion to blood vessels in a subject comprising
administering an anti-P-selectin ligand antibody, thereby inhibiting cell adhesion to
blood vessels.
- 10 40. A method for inhibiting cell adhesion to blood vessels in a subject comprising
administering an anti-P-selectin antibody, thereby inhibiting cell adhesion to blood
vessels.
- 15 41. The method of claim 38, 39, or 40, wherein the adhesive cells are selected from the
group consisting of leukocytes, platelets and endothelial cells.
42. A method for identifying a compound capable of modulating restenosis comprising
assaying the ability of the compound to modulate PSGL-1 protein activity, thereby
20 identifying a compound capable of modulating restenosis.
43. The method of claim 42, wherein the ability of the compound to modulate PSGL-1
polypeptide activity is determined by detecting a decrease in intercellular adhesion.
- 25 44. The method of claim 42, wherein said cellular adhesion involves leukocytes, endothelial
cells, or platelets.
45. The method of claim 42, wherein the ability of the compound to modulate PSGL-1
polypeptide activity is determined by detecting positive vascular remodeling after
30 vascular injury.
46. The method of claim 42, wherein the ability of the compound to modulate PSGL-1
polypeptide activity is determined by detecting a reduction of neointimal formation.

FIG. 1


Platelet adhesion to deeply damaged arterial segments at 1 and 4 hours, and 1 and 4 weeks post-angioplasty in control and rPSGL-Ig-treated animals.



*p, 0.05 vs control

FIG. 2

Neutrophil adhesion to deeply damaged arterial segments at 1 and 4 hours, and 1 and 4 weeks post-angioplasty in control and rPSGL-Ig-treated animals.



*p , 0.05 vs control

FIG. 3

Correlation between vascular stenosis and normalized external elastic lamina (EEL) surface in control and rPSGL-Ig-treated arteries at 4 weeks.




FIG. 4

Correlation between vascular stenosis and neointimal surface in control and rPSGL-Ig-treated arteries at 4 weeks.





FIG. 5


External elastic lamina (EEL) surface and residual lumen in control and rPSGL-Ig-treated arteries at 1 and 4 weeks.



6/6

FIG. 6

Morphology of arterial sections and expression of P-selectin by neoendothelium at 4 weeks in control and rPSGL-Ig-treated arteries.



- 1 -

SEQUENCE LISTING

<110> Genetics Institute, Inc. and Montreal Heart Institute

<120> INHIBITION OF STENOSIS OR RESTENOSIS BY P-SELECTIN ANTAGONISTS

<130> GFN-004PC

<140>

<141>

<160> 13

<170> PatentIn Ver. 2.0

<210> 1

<211> 1649

<212> DNA

<213> Homo sapiens

<400> 1

```

gccacttctt ctgggcccac gaggcagctg tcccatgctc tgctgagcac ggtgggtgcca 60
tgcctctgca actcctcctg ttgctgatcc tactggggccc tggcaacagc ttgcagctgt 120
gggacacctg ggcagatgaa gccagaaaag ccttgggtcc cctgcttgcc cgggaccgga 180
gacaggccac cgaatatgag tacctagatt atgatttcct gccagaaaac gagcctccag 240
aaatgctgag gaacagcact gacaccactc ctctgactgg gcctggaacc cctgagtcta 300
ccactgtgga gcctgctgca aggcgttcta ctggcctgga tgcaggaggg gcagtcacag 360
agctgaccac ggagctggcc aacatgggga acctgtccac ggattcagca gctatggaga 420
tacagaccac tcaaccagca gccacggagg cacagaccac tccactggca gccacagagg 480
cacagacaac tcgactgacg gccacggagg cacagaccac tccactggca gccacagagg 540
cacagaccac tccaccagca gccacggaag cacagaccac tcaaccaca ggctggagg 600
cacagaccac tgcaccagca gccatggagg cacagaccac tgcaccagca gccatggagg 660
cacagaccac tccaccagca gccatggagg cacagaccac tcaaccaca gccatggagg 720
cacagaccac tgcaccagaa gccacggagg cacagaccac tcaaccaca gccacggagg 780
cacagaccac tccactggca gccatggagg ccctgtccac agaaccagt gccacagagg 840
ccctgtccat ggaacctact accaaaagag gtctgttcat acccttttct gtgtcctctg 900
ttactacaaa gggcattccc atggcagcca gcaatttgc cgtcaactac ccagtggggg 960
ccccagacca catctctgtg aagcagtgcc tgctggccat cctaactctg gcgctgggtg 1020
ccactatctt ctctgtgtgc actgtggtgc tggcgggtccg cctctcccgc aagggccaca 1080
tgtaccccggt gcgtaattac tccccaccg agatggtctg catctcatcc ctgttgctg 1140
atgggggtga ggggccctct gccacagcca atgggggcct gtccaaggcc aagagcccgg 1200
gcctgacgcc agagcccagg gaggaccgtg agggggatga cctaccctg cacagcttcc 1260
tcccttagct cactctgcca tctgttttg caagaccca cctccacggg ctctcctggg 1320
ccaccctga gtgccagac cccaatccac agctctgggc ttctcggag acccctgggg 1380
atggggatct tcagggaagg aactctggcc accaaaacag gacaagagca gcctggggcc 1440
aagcagacgg gcaagtggag ccacctctt cctccctccg cggatgaagc ccagccacat 1500
ttcagccgag gtccaaggca ggaggccatt tacttgagac agattctctc ctttttctctg 1560
tccccatct tctctgggtc cctctaact ctcccatggc tctccccgt tctcctggtc 1620
actggagtct cctccccatg tacccaagg 1649

```

<210> 2

<211> 402

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Pro Leu Gln Leu Leu Leu Leu Ile Leu Leu Gly Pro Gly Asn
1           5           10           15

```

- 2 -

Ser Leu Gln Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu
 20 25 30
 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gln Ala Thr Glu Tyr Glu Tyr
 35 40 45
 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg
 50 55 60
 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser
 65 70 75 80
 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly
 85 90 95
 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu
 100 105 110
 Ser Thr Asp Ser Ala Ala Met Glu Ile Gln Thr Thr Gln Pro Ala Ala
 115 120 125
 Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu Ala Gln Thr Thr
 130 135 140
 Arg Leu Thr Ala Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu
 145 150 155 160
 Ala Gln Thr Thr Pro Pro Ala Ala Thr Glu Ala Gln Thr Thr Gln Pro
 165 170 175
 Thr Gly Leu Glu Ala Gln Thr Thr Ala Pro Ala Ala Met Glu Ala Gln
 180 185 190
 Thr Thr Ala Pro Ala Ala Met Glu Ala Gln Thr Thr Pro Pro Ala Ala
 195 200 205
 Met Glu Ala Gln Thr Thr Gln Thr Thr Ala Met Glu Ala Gln Thr Thr
 210 215 220
 Ala Pro Glu Ala Thr Glu Ala Gln Thr Thr Gln Pro Thr Ala Thr Glu
 225 230 235 240
 Ala Gln Thr Thr Pro Leu Ala Ala Met Glu Ala Leu Ser Thr Glu Pro
 245 250 255
 Ser Ala Thr Glu Ala Leu Ser Met Glu Pro Thr Thr Lys Arg Gly Leu
 260 265 270
 Phe Ile Pro Phe Ser Val Ser Ser Val Thr His Lys Gly Ile Pro Met
 275 280 285
 Ala Ala Ser Asn Leu Ser Val Asn Tyr Pro Val Gly Ala Pro Asp His
 290 295 300
 Ile Ser Val Lys Gln Cys Leu Leu Ala Ile Leu Ile Leu Ala Leu Val
 305 310 315 320

- 3 -

Ala Thr Ile Phe Phe Val Cys Thr Val Val Leu Ala Val Arg Leu Ser
 325 330 335

Arg Lys Gly His Met Tyr Pro Val Arg Asn Tyr Ser Pro Thr Glu Met
 340 345 350

Val Cys Ile Ser Ser Leu Leu Pro Asp Gly Gly Glu Gly Pro Ser Ala
 355 360 365

Thr Ala Asn Gly Gly Leu Ser Lys Ala Lys Ser Pro Gly Leu Thr Pro
 370 375 380

Glu Pro Arg Glu Asp Arg Glu Gly Asp Asp Leu Thr Leu His Ser Phe
 385 390 395 400

Leu Pro

<210> 3
 <211> 6
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Restriction
 site

<400> 3
 tctaga

6

<210> 4
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primers

<400> 4
 aactaccag tgggagcacc agaccacatc tctgtgaagc agtgctag

48

<210> 5
 <211> 52
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primers

<400> 5
 aattctagca ctgcttcaca gagatgtggt ctggtgctcc cactgggtag tt

52

<210> 6
 <211> 45
 <212> DNA
 <213> Artificial Sequence

- 4 -

<220>

<223> Description of Artificial Sequence: Primers

<400> 6

aactacccag tgggagcacc agaccacatc tctgtgaagc agtag 45

<210> 7

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primers

<400> 7

aattctactg cttcacagag atgtggtctg gtgctccac tgggtagtt 49

<210> 8

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primers

<400> 8

ctagacccgg gatggcatcc atgacaggag gacaacaaat ggtaggccgt ag 52

<210> 9

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primers

<400> 9

aattctacgg cctacccatt tgttgctctc ctgtcatgga tgccatcccg ggt 53

<210> 10

<211> 13

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primers

<400> 10

ctgcggccgc agt 13

<210> 11

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primers

- 5 -

<400> 11
 ctagactgcg gccgcag 17

<210> 12
 <211> 1587
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)..(1584)

<400> 12
 atg cct ctg caa ctc ctc ctg ttg ctg atc cta ctg ggc cct ggc aac 48
 Met Pro Leu Gln Leu Leu Leu Leu Ile Leu Leu Gly Pro Gly Asn
 1 5 10 15
 agc ttg cag ctg tgg gac acc tgg gca gat gaa gcc gag aaa gcc ttg 96
 Ser Leu Gln Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu
 20 25 30
 ggt ccc ctg ctt gcc cgg gac cgg aga cag gcc acc gaa tat gag tac 144
 Gly Pro Leu Leu Ala Arg Asp Arg Arg Gln Ala Thr Glu Tyr Glu Tyr
 35 40 45
 cta gat tat gat ttc ctg cca gaa acg gag cct cca gaa atg ctg agg 192
 Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg
 50 55 60
 aac agc act gac acc act cct ctg act ggg cct gga acc cct gag tct 240
 Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser
 65 70 75 80
 acc act gtg gag cct gct gca agg cgt tct act ggc ctg gat gca gga 288
 Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly
 85 90 95
 ggg gca gtc aca gag ctg acc acg gag ctg gcc aac atg ggg aac ctg 336
 Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu
 100 105 110
 tcc acg gat tca gca gct atg gag ata cag acc act caa cca gca gcc 384
 Ser Thr Asp Ser Ala Ala Met Glu Ile Gln Thr Thr Gln Pro Ala Ala
 115 120 125
 acg gag gca cag acc act cca ctg gca gcc aca gag gca cag aca act 432
 Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu Ala Gln Thr Thr
 130 135 140
 cga ctg acg gcc acg gag gca cag acc act cca ctg gca gcc aca gag 480
 Arg Leu Thr Ala Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu
 145 150 155 160
 gca cag acc act cca cca gca gcc acg gaa gca cag acc act caa ccc 528
 Ala Gln Thr Thr Pro Pro Ala Ala Thr Glu Ala Gln Thr Thr Gln Pro
 165 170 175
 aca ggc ctg gag gca cag acc act gca cca gca gcc atg gag gca cag 576

- 6 -

Thr Gly Leu Glu Ala Gln Thr Thr Ala Pro Ala Ala Met Glu Ala Gln	
180 185 190	
acc act gca cca gca gcc atg gaa gca cag acc act cca cca gca gcc	624
Thr Thr Ala Pro Ala Ala Met Glu Ala Gln Thr Thr Pro Pro Ala Ala	
195 200 205	
atg gag gca cag acc act caa acc aca gcc atg gag gca cag acc act	672
Met Glu Ala Gln Thr Thr Gln Thr Thr Ala Met Glu Ala Gln Thr Thr	
210 215 220	
gca cca gaa gcc acg gag gca cag acc act caa ccc aca gcc acg gag	720
Ala Pro Glu Ala Thr Glu Ala Gln Thr Thr Gln Pro Thr Ala Thr Glu	
225 230 235 240	
gca cag acc act cca ctg gca gcc atg gag gcc ctg tcc aca gaa ccc	768
Ala Gln Thr Thr Pro Leu Ala Ala Met Glu Ala Leu Ser Thr Glu Pro	
245 250 255	
agt gcc aca gag gcc ctg tcc atg gaa cct act acc aaa aga ggt ctg	816
Ser Ala Thr Glu Ala Leu Ser Met Glu Pro Thr Thr Lys Arg Gly Leu	
260 265 270	
ttc ata ccc ttt tct gtg tcc tct gtt act cac aag ggc att ccc atg	864
Phe Ile Pro Phe Ser Val Ser Ser Val Thr His Lys Gly Ile Pro Met	
275 280 285	
gca gcc agc aat ttg tcc gtc ctg cgg ccg cag tct aga gac aaa act	912
Ala Ala Ser Asn Leu Ser Val Leu Arg Pro Gln Ser Arg Asp Lys Thr	
290 295 300	
cac aca tgc cca ccg tgc cca gca cct gaa ctc ctg ggg gga ccg tca	960
His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser	
305 310 315 320	
gtc ttc ctc ttc ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg	1008
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg	
325 330 335	
acc cct gag gtc aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct	1056
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro	
340 345 350	
gag gtc aag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc	1104
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala	
355 360 365	
aag aca aag ccg cgg gag gag cag tac aac agc acg tac cgt gtg gtc	1152
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val	
370 375 380	
agc gtc ctc acc gtc ctg cac cag gac tgg ctg aat ggc aag gag tac	1200
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr	
385 390 395 400	
aag tgc aag gtc tcc aac aaa gcc ctc cca gtc ccc atc gag aaa acc	1248
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile Glu Lys Thr	
405 410 415	

- 7 -

atc tcc aaa gcc aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg 1296
 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
 420 425 430

ccc cca tcc cgg gag gag atg acc aag aac cag gtc agc ctg acc tgc 1344
 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
 435 440 445

ctg gtc aaa ggc ttc tat ccc agc gac atc gcc gtg gag tgg gag agc 1392
 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
 450 455 460

aat ggg cag ccg gag aac aac tac aag acc acg cct ccc gtg ctg gac 1440
 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
 465 470 475 480

tcc gac ggc tcc ttc ttc ctc tat agc aag ctc acc gtg gac aag agc 1488
 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
 485 490 495

agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct 1536
 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
 500 505 510

ctg cac aac cac tac acg cag aag agc ctc tcc ctg tcc ccg ggt aaa 1584
 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 515 520 525

tag 1587

<210> 13

<211> 528

<212> PRT

<213> Homo sapiens

<400> 13

Met Pro Leu Gln Leu Leu Leu Leu Ile Leu Leu Gly Pro Gly Asn
 1 5 10 15

Ser Leu Gln Leu Trp Asp Thr Trp Ala Asp Glu Ala Glu Lys Ala Leu
 20 25 30

Gly Pro Leu Leu Ala Arg Asp Arg Arg Gln Ala Thr Glu Tyr Glu Tyr
 35 40 45

Leu Asp Tyr Asp Phe Leu Pro Glu Thr Glu Pro Pro Glu Met Leu Arg
 50 55 60

Asn Ser Thr Asp Thr Thr Pro Leu Thr Gly Pro Gly Thr Pro Glu Ser
 65 70 75 80

Thr Thr Val Glu Pro Ala Ala Arg Arg Ser Thr Gly Leu Asp Ala Gly
 85 90 95

Gly Ala Val Thr Glu Leu Thr Thr Glu Leu Ala Asn Met Gly Asn Leu
 100 105 110

- 8 -

Ser Thr Asp Ser Ala Ala Met Glu Ile Gln Thr Thr Gln Pro Ala Ala
 115 120 125
 Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu Ala Gln Thr Thr
 130 135 140
 Arg Leu Thr Ala Thr Glu Ala Gln Thr Thr Pro Leu Ala Ala Thr Glu
 145 150 155 160
 Ala Gln Thr Thr Pro Pro Ala Ala Thr Glu Ala Gln Thr Thr Gln Pro
 165 170 175
 Thr Gly Leu Glu Ala Gln Thr Thr Ala Pro Ala Ala Met Glu Ala Gln
 180 185 190
 Thr Thr Ala Pro Ala Ala Met Glu Ala Gln Thr Thr Pro Pro Ala Ala
 195 200 205
 Met Glu Ala Gln Thr Thr Gln Thr Thr Ala Met Glu Ala Gln Thr Thr
 210 215 220
 Ala Pro Glu Ala Thr Glu Ala Gln Thr Thr Gln Pro Thr Ala Thr Glu
 225 230 235 240
 Ala Gln Thr Thr Pro Leu Ala Ala Met Glu Ala Leu Ser Thr Glu Pro
 245 250 255
 Ser Ala Thr Glu Ala Leu Ser Met Glu Pro Thr Thr Lys Arg Gly Leu
 260 265 270
 Phe Ile Pro Phe Ser Val Ser Ser Val Thr His Lys Gly Ile Pro Met
 275 280 285
 Ala Ala Ser Asn Leu Ser Val Leu Arg Pro Gln Ser Arg Asp Lys Thr
 290 295 300
 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
 305 310 315 320
 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 325 330 335
 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 340 345 350
 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 355 360 365
 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 370 375 380
 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 385 390 395 400
 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Val Pro Ile Glu Lys Thr
 405 410 415

- 9 -

Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	
			420					425					430			
Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	
		435					440					445				
Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	
	450					455					460					
Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	
465					470					475					480	
Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	
				485					490					495		
Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	
			500					505					510			
Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys	
		515					520					525				

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/25007

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/12, 9/64, 15/62; C07K 14/705

US CL : 435/320.1, 6, 7.1, 69.1; 530/350, 300, 387.1; 514, 2, 12.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/320.1, 6, 7.1, 69.1; 530/350, 300, 387.1; 514, 2, 12.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

A_Genseq_36; Issued_Patents_AA; SwissProt_39; PIR_65.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: BIOSIS, MEDLINE, DGENE, HCAPLUS, USPAT, WPIDS, SCISEARCH, BIOTECHABS, BIOTECHDS, EMBASE, WEST.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/30001 A1 (GENETICS INSTITUTE, INC.) 09 November 1995 (9/11/95). See entire document.	1- 18, 22-24 30-46
X	WO 99/65712 A1 (CUMMINGS, ET AL) 23 December 1999 (23/12/99). See entire document.	1-19
X	WO 97/06176 A2 (BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA) 20 February 1997 (20/2/97). See entire document.	1-20, 23-46
X	WO 94/10309 A1 (GENETICS INSTITUTE, INC.) 11 May 1994 (11/5/94). See entire document.	1-18, 21, 22

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 NOVEMBER 2000

Date of mailing of the international search report

28 DEC 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HOPE ROBINSON

Telephone No. (703) 308-0196